Atara Biotherapeutics (ATRA) Net Shares Issued and Repurchased (2014 - 2026)

Atara Biotherapeutics (ATRA) has reported Net Shares Issued and Repurchased for 13 consecutive years, with $235.0 the latest figure, recorded in Q1 2026.

• For the quarter ending Q1 2026, Net Shares Issued and Repurchased fell 99.14% year-over-year to $235.0; the trailing twelve-month figure through Mar 2026 stood at $235.0 (down 99.14% YoY), and the FY2025 full-year result was $160478.0, up 872.59% from the prior year.
• Net Shares Issued and Repurchased retreated to $235.0 in Q1 2026 per ATRA's latest filing, from $160478.0 in the prior quarter.
• Across five years, Net Shares Issued and Repurchased topped out at $4.1 million in Q1 2023 and bottomed at $235.0 in Q1 2026.
• Historically, Net Shares Issued and Repurchased has averaged $1.3 million across 5 years, with a median of $187756.0 in 2023.
• The sharpest annual moves came in 2025 and 2026: Net Shares Issued and Repurchased soared 872.59% in 2025, then tumbled 99.14% in 2026.
• Over 5 years, Net Shares Issued and Repurchased stood at $3.6 million in 2022, then slumped by 94.81% to $187756.0 in 2023, then tumbled by 91.21% to $16500.0 in 2024, then jumped by 872.59% to $160478.0 in 2025, then slumped by 99.85% to $235.0 in 2026.
• According to Business Quant data, Net Shares Issued and Repurchased over the past three periods registered $235.0, $160478.0, and $27388.0 for Q1 2026, Q4 2025, and Q1 2025 respectively.